IMI offers €12.2m for better ways of testing effectiveness of flu vaccines
This article was originally published in Scrip
€12.2m in EU funding is being made available for new ideas on how to develop standardised tests that can more accurately determine how effective a new influenza vaccine is likely to be. The funding is being offered by Europe's Innovative Medicines Initiative (IMI), a joint undertaking between the pharmaceutical industry federation EFPIA and the European Commission.
You may also be interested in...
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.